title: Impact of genetic polymorphism of SDF1 3A on efficacy of captopril in Chinese patients with essential hypertension.
abstract: OBJECTIVE
  To explore the association of SDF1 3A genetic polymorphism with susceptibility of essential hypertension and captopril efficacy in patients with essential hypertension.
  
  
  METHODS
  A total of 214 patients with essential hypertension and 228 healthy controls were genotyped for SDF1 3A polymorphism by polymerase chain reaction-restriction fragment length polymorphism assay. Among 39 subjects with different SDF1 3A of genotypes, 13 hypertensive patients simultaneously took oral captopril (25 mg/d) and nitrendipine (30 mg/d), and 12 patients orally received nitrendipine alone for 8 consecutive weeks, and 14 healthy controls did not take any agents. The blood pressure of all subjects was measured to evaluate the therapeutic efficacy.
  
  
  RESULTS
  There was a significant difference in the plasma SDF-1 level in individuals with AA+AG genotypes or GG genotypes of SDF1 3A treated with nitrendipine plus captopril compared with healthy control (P < 0.05). Carriers with AA genotypes of SDF1 3A had lower total protein and globulin than those with GG genotypes (P < 0.05). After captopril treatment, hypertensive patients with AA+AG genotypes had bigger attenuated systolic blood pressure compared with those with GG genotypes (P < 0.05).
  
  
  CONCLUSIONS
  Genetic polymorphism of SDF1 3A could influence the therapeutic efficacy of captopril in Chinese hypertensive patients.
authors.affiliation: Department of Cardiology, Xiangya Hospital, Central South University, Changsha 410008, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Yan
authors.forename: Chen
authors.initials: C
authors.lastname: Ning
authors.forename: Huan
authors.initials: H
authors.lastname: Zhou
authors.forename: Xiheng
authors.initials: X
authors.lastname: Yang
authors.forename: Tianlun
authors.initials: T
authors.lastname: Yang
authors.forename: Zhaoqian
authors.initials: Z
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001483:Base Sequence; D002216:Captopril / Q000627:therapeutic use*; D016022:Case-Control Studies; D054377:Chemokine CXCL12 / Q000235:genetics*; D005260:Female; D005838:Genotype; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D012150:Polymorphism, Restriction Fragment Length
chemical_list: D000959:Antihypertensive Agents; D054377:Chemokine CXCL12; D002216:Captopril